Article
First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis.
British journal of cancer - 1 Mar 2021
van Breeschoten Jesper, Wouters Michel W J M, Hilarius Doranne L, Haanen John B, Blank Christian U, Aarts Maureen J B, van den Berkmortel Franchette W P J, de Groot Jan-Willem B, Hospers Geke A P, Kapiteijn Ellen, Piersma Djura, van Rijn Roos S, Suijkerbuijk Karijn P M, Blokx Willeke A M, Tije Bert-Jan J Ten, Veldt Astrid A M van der, Vreugdenhil Art, Boers-Sonderen Marye J, van den Eertwegh Alfonsus J M
Abstract excerpt
BACKGROUND: Anti-PD-1 antibodies and BRAF/MEK inhibitors are the two main groups of systemic therapy in the treatment of BRAFV600-mutant advanced melanoma. Until now, data are inconclusive on which therapy to use as first-line treatment. The aim of this study was to use propensity score matching to compare first-line anti-PD-1 monotherapy vs. BRAF/MEK inhibitors in advanced BRAFV600-mutant melanoma patients....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.